{"id":38199,"date":"2025-07-30T12:58:35","date_gmt":"2025-07-30T04:58:35","guid":{"rendered":"https:\/\/flcube.com\/?p=38199"},"modified":"2025-07-30T12:58:36","modified_gmt":"2025-07-30T04:58:36","slug":"bayers-sevabertinib-granted-priority-review-by-chinas-nmpa-for-nsclc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38199","title":{"rendered":"Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment"},"content":{"rendered":"\n

German pharmaceutical giant Bayer AG (ETR: BAYN<\/a>) announced on July 28, 2025, that the marketing application for its targeted therapy, Sevabertinib, has been accepted by China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) and granted priority review status. Sevabertinib is an oral small-molecule tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 activating mutations. These patients have previously received at least one systemic therapy. The marketing application in China was submitted concurrently with filings in the United States and other global countries.<\/p>\n\n\n\n

Drug Mechanism and Development<\/strong>
Sevabertinib targets HER2 exon 20 insertion mutations and point mutations, demonstrating high selectivity for both mutant HER2 and EGFR. The application is based on positive results from the SOHO-01 Phase I\/II trial. In this trial, the drug showed an objective response rate of 71% in advanced NSCLC patients who had received prior systemic therapy but no prior HER2-targeted TKI. The safety profile was favorable and consistent with previous reports.<\/p>\n\n\n\n

Previous Designation<\/strong>
Previously, Sevabertinib had been granted Breakthrough Therapy Designation by the CDE, underscoring its potential to address significant unmet medical needs in this patient population.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing…<\/p>\n","protected":false},"author":1,"featured_media":38200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[269,16,967,15],"class_list":["post-38199","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-cancer","tag-etr-bayn","tag-product-approvals"],"yoast_head":"\nBayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing application for its targeted therapy, Sevabertinib, has been accepted by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) and granted priority review status. Sevabertinib is an oral small-molecule tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 activating mutations. These patients have previously received at least one systemic therapy. The marketing application in China was submitted concurrently with filings in the United States and other global countries.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38199\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing application for its targeted therapy, Sevabertinib, has been accepted by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) and granted priority review status. Sevabertinib is an oral small-molecule tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 activating mutations. These patients have previously received at least one systemic therapy. The marketing application in China was submitted concurrently with filings in the United States and other global countries.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38199\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T04:58:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-30T04:58:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3006.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment\",\"datePublished\":\"2025-07-30T04:58:35+00:00\",\"dateModified\":\"2025-07-30T04:58:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199\"},\"wordCount\":210,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3006.webp\",\"keywords\":[\"Bayer\",\"Cancer\",\"ETR: BAYN\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38199#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38199\",\"name\":\"Bayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3006.webp\",\"datePublished\":\"2025-07-30T04:58:35+00:00\",\"dateModified\":\"2025-07-30T04:58:36+00:00\",\"description\":\"German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing application for its targeted therapy, Sevabertinib, has been accepted by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) and granted priority review status. Sevabertinib is an oral small-molecule tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 activating mutations. These patients have previously received at least one systemic therapy. The marketing application in China was submitted concurrently with filings in the United States and other global countries.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38199\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3006.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/3006.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38199#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing application for its targeted therapy, Sevabertinib, has been accepted by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) and granted priority review status. Sevabertinib is an oral small-molecule tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 activating mutations. These patients have previously received at least one systemic therapy. The marketing application in China was submitted concurrently with filings in the United States and other global countries.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38199","og_locale":"en_US","og_type":"article","og_title":"Bayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment","og_description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing application for its targeted therapy, Sevabertinib, has been accepted by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) and granted priority review status. Sevabertinib is an oral small-molecule tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 activating mutations. These patients have previously received at least one systemic therapy. The marketing application in China was submitted concurrently with filings in the United States and other global countries.","og_url":"https:\/\/flcube.com\/?p=38199","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-30T04:58:35+00:00","article_modified_time":"2025-07-30T04:58:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3006.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38199#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38199"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment","datePublished":"2025-07-30T04:58:35+00:00","dateModified":"2025-07-30T04:58:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38199"},"wordCount":210,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38199#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3006.webp","keywords":["Bayer","Cancer","ETR: BAYN","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38199#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38199","url":"https:\/\/flcube.com\/?p=38199","name":"Bayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38199#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38199#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3006.webp","datePublished":"2025-07-30T04:58:35+00:00","dateModified":"2025-07-30T04:58:36+00:00","description":"German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing application for its targeted therapy, Sevabertinib, has been accepted by China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) and granted priority review status. Sevabertinib is an oral small-molecule tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 activating mutations. These patients have previously received at least one systemic therapy. The marketing application in China was submitted concurrently with filings in the United States and other global countries.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38199#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38199"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38199#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3006.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3006.webp","width":1080,"height":608,"caption":"Bayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38199#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/3006.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38199"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38199\/revisions"}],"predecessor-version":[{"id":38201,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38199\/revisions\/38201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38200"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}